Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09ZWH
|
|||
| Former ID |
DNCL001664
|
|||
| Drug Name |
LX2931
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hereditary acantholytic dermatoses [ICD-11: EC20.2; ICD-10: Q82.8] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [2] | ||
| Company |
Lexicon Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H15N3O5
|
|||
| Canonical SMILES |
CC(=NO)C1=NC=C(N1)C(C(C(CO)O)O)O
|
|||
| InChI |
1S/C9H15N3O5/c1-4(12-17)9-10-2-5(11-9)7(15)8(16)6(14)3-13/h2,6-8,13-17H,3H2,1H3,(H,10,11)/b12-4+/t6-,7-,8-/m1/s1
|
|||
| InChIKey |
AMXVYJYMZLDINS-RSWLNLDNSA-N
|
|||
| CAS Number |
CAS 948840-25-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine-1-phosphate lyase 1 (SGPL1) | Target Info | Inhibitor | [3], [4] |
| KEGG Pathway | Sphingolipid metabolism | |||
| Metabolic pathways | ||||
| Sphingolipid signaling pathway | ||||
| Pathwhiz Pathway | Sphingolipid Metabolism | |||
| Pathway Interaction Database | Sphingosine 1-phosphate (S1P) pathway | |||
| Reactome | Sphingolipid de novo biosynthesis | |||
| WikiPathways | Sphingolipid metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT00903383) Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate. U.S. National Institutes of Health. | |||
| REF 3 | Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. | |||
| REF 4 | S1P is associated with protection in human and experimental cerebral malaria. Mol Med. 2011;17(7-8):717-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.